Showing 3951-3960 of 4953 results for "".
- Pilot Study: ESWT Improves Wound Healing Before Surgeryhttps://practicaldermatology.com/news/pilot-study-eswt-improves-wound-healing-before-surgery/2460032/Extracorporeal shockwaves (ESWT) initiated within the operation field prior to surgery may improve wound healing and minimize scar formation, according to a pilot study in Lasers in Surgery and Medicine (LSM). The
- ASA Honors Outstanding Researchershttps://practicaldermatology.com/news/asa-honors-outstanding-researchers/2460029/Luis Diaz, MD of the University of North Carolina, Chapel Hill and John Stanley, MD of the University of Pennsylvania took home the American Skin Association’s David Martin Carter Mentor Award at the Annual Meeting of t
- Abeona Therapeutics to Present EB-101 Data at Society for Investigative Dermatology Annual Meetinghttps://practicaldermatology.com/news/abeona-therapeutics-to-present-eb-101-data-at-society-for-investigative-dermatology-annual-meeting/2460024/Long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID) in Chicago. The data will be presented by Stanfor
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Aesthetic Innovations Summit Coming to New Orleanshttps://practicaldermatology.com/news/aesthetic-innovations-summit-coming-to-new-orleans/2460022/Coming off an impressive inaugural meeting in 2018, the second annual Aesthetics Innovation Summit will unite over 300 of the most influential corporate, capital, and clinical leaders in New Orleans to collaborate on the development and adoption of new aesthetic treatments and technologies.
- ISHRS Awareness Campaign Takes on Black Market Hair Restoration Clinicshttps://practicaldermatology.com/news/ishrs-awareness-campaign-takes-on-black-market-hair-restoration-clinics/2460016/The International Society of Hair Restoration Surgery (ISHRS) is launching a new public awareness campaign to help patients recognize “black market pirate” hair restoration clinics and misleading advertising claims. Social media engagement will be the cornerstone of the new
- Happy 10th Birthday Dysport!https://practicaldermatology.com/news/happy-10th-birthday-dysport/2460015/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in the ASPIRE Rewards program through July 31
- Xstrahl Introduces UpGraded Treatment System for Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/xstrahl-introduces-upgraded-treatment-system-for-non-melanoma-skin-cancer/2460011/Xstrahl Medical is launching its latest superficial radiotherapy treatment system to treat the full range of non-melanoma skin cancer cases. The new Xstrahl 150 system offers several features that enhance the capabilities of Xstrahl's curr
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol prop